Biotech Industry · global
GSK to Acquire Trispecific Cancer Drug Rights for Up to $750 Million, Expanding Its Multiple Myeloma Pipeline
Could simultaneously engaging T cells and two tumor antigens deliver more durable, better-tolerated treatment? GSK’s agreement to acquire global rights from Chimagen bets on a design that has yet to be validated in human trials.
Enabling immune cells to attack cancer more precisely while reducing the burden of treatment is a key challenge in developing new drugs for multiple myeloma. On September 15, 2026, GSK announced that it had signed an agreement with Chinese biotech company Chimagen Biosciences to acquire full global rights to a trispecific T-cell engager (TCE), in a deal potentially worth up to $750 million. The program is expected to enter Phase 1 clinical trials in 2027.
The amount includes an upfront payment and milestone payments contingent on development and commercial outcomes; it is not a single payment made at signing. Cooley, the law firm that assisted Chimagen with the transaction, also confirmed the transfer of global rights and the payment structure. The parties did not disclose the specific upfront amount in their announcements. According to GSK’s announcement, the agreement remains subject to customary closing conditions.
The drug candidate is designed to engage T cells at one end while recognizing two tumor-associated antigens, thereby directing an immune attack. GSK said it hopes this trispecific design can deliver deeper, more durable responses and improve tolerability. However, the announcement did not disclose the names of the two tumor antigens or provide detailed experimental data sufficient to compare efficacy and safety.
In multiple myeloma, efficacy and tolerability must be considered together. GSK noted that TCEs have demonstrated therapeutic potential but continue to face tolerability challenges in use. If the new design can improve the balance between the two, it could broaden opportunities for use. However, this remains a development goal and does not establish that the candidate is superior to existing therapies, much less that it is already suitable for use earlier in treatment.
The agreement also extends the relationship between the two companies. GSK previously acquired Chimagen’s CMG1A46, a program targeting CD19 and CD20 that is distinct from the new multiple myeloma candidate covered by this agreement. Cooley said it was also involved in the earlier transaction. The successive acquisitions of different programs indicate that GSK continues to strengthen its hematology research and development pipeline through external assets.
Human trials will provide the real test of this investment. The Phase 1 study will be an important starting point for understanding safety, dosing, and preliminary activity. How long responses last, whether tolerability improves, and whether therapeutic uses can be expanded will all require subsequent clinical evidence. The deal structure, worth up to $750 million, reflects a valuation of the program’s research and development potential; multiple hurdles remain before it could become a new therapy available to patients.